Targeted therapies in bladder cancer: an overview of in vivo research.
about
Recent Advances of Light-Mediated Theranostics.Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells.Anti-tumor effects of Atractylenolide I on bladder cancer cells.Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrenceEfficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies.Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell.ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasionNiclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling.BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB AlterationsSuppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.YAP regulates ALDH1A1 expression and stem cell property of bladder cancer cells
P2860
Q28077517-3D66045C-995E-45D2-8E55-54DE7801DF7AQ33593041-85544648-B4AD-4C29-BE07-9E6F1EB1E1D2Q33668999-F5DA1E33-897B-47F3-834C-2305BEFEAD62Q33762681-5D4F559D-59E2-41C7-B52D-01431BAD64E3Q36639263-0FDCCB65-336A-4EC5-8408-1E925AD23B34Q37046554-33DD4B80-59A9-47C0-AF7D-FCC3321B69F9Q37249063-06B07A61-0478-44C3-87EC-8E1699E8B36AQ37427970-0729BC9E-3273-4271-8C2F-9DC0F5D1174FQ37619797-CEAE8944-25B6-4F10-9D05-CFD7F7B6D687Q37725643-133FFF7D-EA30-42F2-9C83-4A53D8A2C237Q38619027-D2F600A8-82EE-4D30-969F-DAF0021CD660Q39156389-ADC8410F-5786-4612-81F5-46503E2464F1Q39863683-5820BD5F-D332-4877-9340-CB4C4008996AQ49456418-0FB13B88-9A74-4E5A-B818-704CCCEDEB59Q52323640-40D60B15-5DFD-4A72-A39F-49E9A1AF72BDQ55397522-2A091E48-1EE2-403E-ABAD-D21D2DED169DQ57816335-06A5624A-5355-40E4-8C76-AED00DC1E2A9
P2860
Targeted therapies in bladder cancer: an overview of in vivo research.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeted therapies in bladder cancer: an overview of in vivo research.
@en
type
label
Targeted therapies in bladder cancer: an overview of in vivo research.
@en
prefLabel
Targeted therapies in bladder cancer: an overview of in vivo research.
@en
P2093
P2860
P356
P1476
Targeted therapies in bladder cancer: an overview of in vivo research.
@en
P2093
Arnout R Alberts
Ellen C Zwarthoff
Joost L Boormans
Kim E M van Kessel
Tahlita C M Zuiverloon
P2860
P2888
P304
P356
10.1038/NRUROL.2015.231
P407
P577
2015-09-22T00:00:00Z
P5875
P6179
1045654754